Sagimet Biosciences, Inc. Class A's total assets for Q4 2024 were $160.26M, a decrease of -8.31% from the previous quarter. SGMT total liabilities were $4.45M for the fiscal quarter, a 8.85% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.